These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 8531144
1. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG. J Pharmacol Exp Ther; 1995 Dec; 275(3):1681-7. PubMed ID: 8531144 [Abstract] [Full Text] [Related]
2. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N. Cancer Res; 1991 Jun 15; 51(12):3237-42. PubMed ID: 1645616 [Abstract] [Full Text] [Related]
3. Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. Nakano M, Sogawa CA, Sogawa N, Mishima K, Yamachika E, Mizukawa N, Fukunaga J, Kawamoto T, Sawaki K, Sugahara T, Furuta H. Anticancer Res; 2003 Jun 15; 23(1A):299-303. PubMed ID: 12680227 [Abstract] [Full Text] [Related]
4. Basal and zinc-induced metallothionein in resistance to cadmium, cisplatin, zinc, and tertbutyl hydroperoxide: studies using MT knockout and antisense-downregulated MT in mammalian cells. Kennette W, Collins OM, Zalups RK, Koropatnick J. Toxicol Sci; 2005 Dec 15; 88(2):602-13. PubMed ID: 16150881 [Abstract] [Full Text] [Related]
5. Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. Yang YY, Woo ES, Reese CE, Bahnson RR, Saijo N, Lazo JS. Mol Pharmacol; 1994 Mar 15; 45(3):453-60. PubMed ID: 7511778 [Abstract] [Full Text] [Related]
6. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Koropatnick J, Pearson J. Mol Pharmacol; 1993 Jul 15; 44(1):44-50. PubMed ID: 8341278 [Abstract] [Full Text] [Related]
7. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Langton-Webster BC, Xuan JA, Brink JR, Salomon DS. Cell Growth Differ; 1994 Dec 15; 5(12):1367-72. PubMed ID: 7696185 [Abstract] [Full Text] [Related]
8. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Cancer Res; 1995 Feb 01; 55(3):474-7. PubMed ID: 7834610 [Abstract] [Full Text] [Related]
9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N, Lam YM, Pym J, Campling BG. Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677 [Abstract] [Full Text] [Related]
10. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI. Cancer Res; 1988 Jun 15; 48(12):3355-9. PubMed ID: 2897238 [Abstract] [Full Text] [Related]
11. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Clin Cancer Res; 1996 Feb 15; 2(2):427-32. PubMed ID: 9816187 [Abstract] [Full Text] [Related]
12. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E. Cancer Res; 1987 Jan 15; 47(2):388-93. PubMed ID: 3539321 [Abstract] [Full Text] [Related]
13. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Deng HB, Adikari M, Parekh HK, Simpkins H. Cancer Chemother Pharmacol; 2004 Oct 15; 54(4):301-7. PubMed ID: 15138708 [Abstract] [Full Text] [Related]
14. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells. Oguchi H, Kikkawa F, Kojima M, Maeda O, Mizuno K, Suganuma N, Kawai M, Tomoda Y. Anticancer Res; 1994 Oct 15; 14(1A):193-200. PubMed ID: 7909418 [Abstract] [Full Text] [Related]
15. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H. Anticancer Res; 2008 Oct 15; 28(4B):2087-92. PubMed ID: 18751380 [Abstract] [Full Text] [Related]
16. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Ikeguchi M, Nakamura S, Kaibara N. Oncol Rep; 2002 Oct 15; 9(5):1121-6. PubMed ID: 12168083 [Abstract] [Full Text] [Related]
17. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Mizutani Y, Yoshida O, Bonavida B. J Urol; 1998 Aug 15; 160(2):561-70. PubMed ID: 9679929 [Abstract] [Full Text] [Related]
18. Possible mechanism responsible for the acquisition of resistance to cis-diamminedichloroplatinum (II) by cultured human testicular seminoma cells. Kobayashi T, Fujii T, Jo Y, Kinugawa K, Fujisawa M. J Urol; 2004 May 15; 171(5):1929-33. PubMed ID: 15076314 [Abstract] [Full Text] [Related]
19. The protective effect of metallothionein against lipid peroxidation caused by retinoic acid in human breast cancer cells. Hurnanen D, Chan HM, Kubow S. J Pharmacol Exp Ther; 1997 Dec 15; 283(3):1520-8. PubMed ID: 9400029 [Abstract] [Full Text] [Related]
20. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. Clin Cancer Res; 2000 Jan 15; 6(1):193-202. PubMed ID: 10656450 [Abstract] [Full Text] [Related] Page: [Next] [New Search]